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Management Programs for Diabetes in 2003 leading to intensification of antihyper-
glycemic therapy and thus increasing the risk for SH.
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OBJECTIVES: Hypoglycaemia is a major side effect of antidiabetes drugs. Mild ep-
isodes of hypoglycaemia are frequent and are generally self-treated. On the other
hand, severe hypoglycaemia can have deleterious effects on mortality, morbidity
and quality of life. The objective was to describe the burden of severe hypoglycae-
mia among new users of insulin and oral antidiabetes drugs (OAD) in terms of two
hypoglycaemia-related outcomes: emergency department (ED) visit and hospital-
ization. More specifically: 1) to describe the frequency of hypoglycaemia-related ED
visits and hospitalizations, and 2) to calculate the incidence rate of these two
outcomes. METHODS: We conducted an inception cohort study using the data-
bases of the Quebec health insurance board and the Quebec registry of hospital-
izations. The source population was made of individuals aged 18 years or over;
newly dispensed an antidiabetes treatment made of either insulin or OAD between
January 1, 2000 and December 31, 2008. Individuals were followed from initiation of
antidiabetes treatment to December 31, 2008, occurrence of hypoglycaemia-related
outcome, loss of eligibility to the drug plan or death, whichever came first. Individ-
uals’ characteristics at antidiabetes treatment initiation were described using fre-
quency distributions. The incidence rate for the occurrence of hypoglycaemia-
related ED visit and hypoglycaemia-related hospitalization were calculated using
the Kaplan–Meier method. RESULTS: A total of 188,659 new users of antidiabetes
treatment were included in the cohort. A total of 3575 (1.9%) individuals had at least
one hypoglycaemia-related ED visit while 194 (0.1%) had at least one hypoglycae-
mia-related hospitalization. Incidence rates for the occurrence of hypoglycaemia-
related ED visits and hypoglycaemia-related hospitalizations were 5.2, and 0.3
cases per 1000 patient-years, respectively. CONCLUSIONS: Although the incidence
of ED visit or hospitalization due to hypoglycaemia seems low, severe hypoglycae-
mia episodes could be associated with a high economic burden.
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OBJECTIVES: To assess whether the presence of type 2 diabetes mellitus (T2DM)
increases the risk of urinary tract infections (UTI) in men and women. METHODS:
In a retrospective cohort study, patients 18 years with a diagnosis of T2DM or
prescriptions for antihyperglycaemic therapy were identified within MarketScan, a
US-based insurance claims database. Date of first T2DM diagnosis or prescription
in 2008 was the index date. Patients without T2DM were age and gender matched to
those with T2DM. Eligible patients had medical records for 1 year prior to (baseline)
and 1 year after (follow up) the index date. UTI diagnosis during follow up was
assessed with ICD-9 codes. Logistic regression adjusted for patient characteristics
and comorbid conditions was used to assess the likelihood of experiencing UTI.
RESULTS: A total of 106,623 matched pairs were selected. The mean age at index
date was 56 years and 50% were male. Patients with T2DM had more pre-existing
comorbid conditions compared to patients without T2DM. In the 1-year follow up,
more patients with T2DM were diagnosed with UTI (12.9% vs. 7.7%; p0.0001)
compared to non-T2DM patients. The proportion of women with T2DM experienc-
ing UTI was greater (18.3% vs. 11.8%; p0.0001) than for women without T2DM. A
lower proportion of men had UTI, but the difference between T2DM and no T2DM
remained and was significant (7.6% vs. 3.6%; p0.0001). In a logistic regression,
patients with T2DM had a greater likelihood of experiencing UTI during follow up
(adjusted odds ratio 1.71 [95% CI 1.66, 1.77]). For each gender alone, the odds were
still significantly greater for patients with T2DM. Measurements of glycemic con-
trol were not available and thus their influence on UTI risk could not be assessed.
CONCLUSIONS: Patients with T2DM were more likely to experience a UTI com-
pared to patients without T2DM.
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OBJECTIVES:Analog insulin glulisine has a higher efficacy in reducing postprandial
glucose excursions and in restoring normal postprandial microcirculation than
regular human insulins. Besides glycemic control, insulin glulisine has also favor-
able effects in maintaining normal endothelial function. Therefore, the aim was to
compare the incidence of macro- and microvascular outcomes in type 2 diabetic
patients treated with insulin glulisine or regular human insulin. METHODS: Com-
puterized data from 952 glulisine (age: 61 11 yrs) and 11,157 regular insulin (65
11 yrs) users in general practices throughout Germany (Disease Analyzer, 11/2004
to 3/2010) were analysed. Hazard ratios (HR; Cox regression) for 3.5-year risk of
macro- or microvascular outcomes were adjusted for age, sex, diabetes duration,
health insurance, residency, diabetologist care, hypertension, hyperlipidemia, de-
pression, and co-medication (basal insulin, oral antidiabetics). Furthermore, ad-
justment was carried out for baseline microvascular complications when analyz-
ing macrovascular outcomes and vice versa.RESULTS:Overall, risk for both macro-
and microvascular outcomes was 20% lower for patients using insulin glulisine
(p0.05). There was a decreased risk for coronary heart disease (HR; 95% CI: 0.78;
0.62–0.99), and a trend for lower events of myocardial infarction (0.66; 0.43–1.02).
Also for microvascular complications, the adjusted hazard ratios for retinopathy,
nephropathy and neuropathy were below 1.0, indicating a lower risk for the insulin
glulisine group, however, which was statistically significant for neuropathy only
(0.74; 0.58–0.93). CONCLUSIONS: The prescription of the rapid-acting insulin ana-
log glulisine was associated with a reduced incidence of macro- and microvascular
outcomes in type 2 diabetes under real-life conditions in a retrospective database
analysis. It is important to confirm this finding in a randomized controlled trial.
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OBJECTIVES: The World Health Organization has recognized diabetes and other
selected chronic health conditions are at an epidemic level all of which can be
impacted by weight. The purpose of this project was to classify US adults by Body
Mass Index (BMI) categories and compare adults with diabetes to those adults
without diabetes by BMI categories and other selected priority health conditions to
see if there was a difference between groups. METHODS: The Medical Expenditure
Panel Survey (MEPS) is publically available database providing nationally represen-
tative estimates of health care use, expenditures, sources of payment, and health
insurance coverage for the US population. Analysis of the survey data utilized
design-based methods that utilized the complex survey stratification and weight-
ing provided within the MEPS datasets, in addition to use of the Rao-Scott Chi-
square test, to compare people with and without diabetes. The level of significance
was two-tailed 0.05. RESULTS: In 2008, approximately 64 percent of the U.S.
adult population was overweight (BMI of 25.0 to 29.9), obese (BMI of 30.0 to 39.9), or
extremely obese (BMI greater than or equal to 40). Adults with diabetes had signif-
icantly higher percentages of being overweight, obese, and extremely obese, where
more likely to have asthma and more than twice as likely to have hypertension,
and were nearly three times as likely to have heart disease and more than three
times more likely to have a stroke than adults without diabetes (p-value0.001).
CONCLUSIONS: Patients with diabetes were more likely to be overweight, obese,
and extremely obese compared to those without diabetes. Patients with diabetes
were also more likely to have chronic health conditions such as hypertension,
heart disease, and stroke.
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OBJECTIVES: To determine the prevalence and incidence of Lantus vs NPH and
premix insulin use in diabetes including the treatment characteristics, comorbidity
and resource use in a representative population in Canada. METHODS: Records
from a longitudinal population-based database of more than 225,000 primary care
patients in southwestern Ontario, Canada were analyzed between January 1 2008
to September 30 2010. Patients were considered to have diabetes if at least one of
the following conditions was met: 1) physician diagnosed type 1 or 2 diabetes; 2)
1 measurement of HbA1 greater than the recommended target; or 3) at least one
prescription for a diabetes medication. RESULTS: A total of 76,077 adult patients
with representative data were included between 2008-2010. Prevalence of T2DM
was 7.9% and Type 1 diabetes was 2.9%. Patients on Lantus had less hypertension,
nephropathy or Stage 5 kidney disease than NPH or Premix insulin patients
(p0.05). Patients receiving Premix insulin tended to have more primary care visits,
ER visits, hospitalizations and total referrals than Lantus. More patients received
new scripts for NPH than Lantus or Premix insulin during the study period. The
average dose of Lantus was 10.5-10.7 units, with a high rate of annual renewal
(89.8-96.6%) for the same dose or any dose (93.8-98.7%). There were very few dose
switches or discontinuations for Lantus while NPH and Premix insulin were re-
newed less, underwent more dose switches and less discontinuations.
CONCLUSIONS: In a real-world setting the prevalence of diabetes was similar to
nationally reported data. Patients receiving Lantus tended to have less hyperten-
sion, nephropathy or Stage 5 kidney disease, while those who took Premix insulin
utilized more health services than Lantus or NPH. Lantus scripts were renewed
more often, had less dose changes or switches and less discontinuations than NPH
or Premix insulin.
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